Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 612 matching trials from the live ClinicalTrials.gov search.
Conditions
Heart Failure, Acute Kidney Injury
Interventions
Dapagliflozin 10mg Tab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut
Conditions
IGT - Impaired Glucose Tolerance, T2D
Interventions
Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test, Hyperinsulinemic Euglycemic Clamp and 2H20
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
12 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Diabetes Mellitus, Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Natriuretic Peptides, Metabolism, Energy Expenditure
Interventions
Sacubitril, Valsartan 97-103 mg Oral Tablet, Valsartan 160 mg, Intravenous Glucose Tolerance Test, Standardized Meals, Exercise capacity VO2 maximum determination
Drug · Other · Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Diabetes Mellitus, Cancer
Interventions
Oral Glucose Tolerance Test (OGTT), 2 OGTTs with and without GLP-1 analogue, Hyperglycemic clamp procedure
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Pancreatic Neoplasms, Bile Duct Neoplasms
Interventions
Oxaliplatin, Capecitabine, Sorafenib
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Diabetes Mellitus, Type 2
Interventions
Orforglipron, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
17
States / cities
Sacramento, California • San Diego, California • Stamford, Connecticut + 14 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
929 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
74
States / cities
Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Bethanechol on Glucose Homeostasis

NCT01434901
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Bethanechol (25 mg), Bethanechol (50 mg), Bethanechol (100 mg)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Recruiting Not applicable Interventional Accepts healthy volunteers

Night Owl Metabolism

NCT06507722
Conditions
PreDiabetes, Overweight, Impaired Glucose Tolerance
Interventions
Timing of OGTT, Timing of Standardized Meal
Diagnostic Test · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 23 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Obesity
Interventions
Exendin 9-39 and Sitagliptin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Type 2 Diabetes
Interventions
vitamin D3, cholecalciferol, Inactive comparator
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
19 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Postoperative Pain Control, Opioid Consumption
Interventions
Ketamine, Placebo Ketamine, Lidocaine, Placebo Lidocaine, Acetaminophen, Placebo Acetaminophen, Gabapentin, Placebo Gabapentin, Celecoxib, Placebo Celecoxib
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)

NCT02145247
Conditions
Polycystic Ovary Syndrome
Interventions
hCG
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
La Jolla, California
Conditions
Critical Illness, Acute Respiratory Failure
Interventions
Olimel (5.7%E / N9E)
Drug
Lead sponsor
Clinical Evaluation Research Unit at Kingston General Hospital
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Boulder, Colorado • St Louis, Missouri • Cleveland, Ohio + 3 more
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Oral combined hormonal contraceptives
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 49 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
51
States / cities
Birmingham, Alabama • Guntersville, Alabama • Phoenix, Arizona + 42 more
Completed Phase 4 Interventional Results available

Mechanisms of Weight Loss With SGLT2 Inhibition

NCT02360774
Conditions
Type 2 Diabetes, Overweight, Obesity
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • San Antonio, Texas
Completed Not applicable Interventional Accepts healthy volunteers

Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk

NCT01104220
Conditions
Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Metabolically Abnormal Obesity, Metabolically Normal Obesity, Obesity
Interventions
Weight loss
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Hot Water Immersion on Heart Rate Variability and Glucose

NCT06193291
Conditions
Glucose Tolerance, HRV
Interventions
Feet heating, Calf heating
Procedure
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Diego, California
Conditions
Major Depressive Disorder
Interventions
Empagliflozin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Gestational Diabetes, Pregnancy Related
Interventions
Observational
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
2,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
New Haven, Connecticut • Honolulu, Hawaii • Chicago, Illinois + 5 more
Not listed Not applicable Interventional Accepts healthy volunteers

Ketone Supplements and Substrate Oxidation and Physical Performance

NCT04737694
Conditions
Ketosis, Glucose Metabolism
Interventions
Ketone ester, Glucose
Dietary Supplement
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 39 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Natick, Massachusetts
Conditions
Gestational Diabetes
Interventions
2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina